Stevanato Group delivered solid fourth-quarter performance with revenue growth driven by its Biopharmaceutical and Diagnostic Solutions segment and strong demand for high-value solutions. Profitability improved with higher gross margins and expanded adjusted EBITDA margins despite a decline in the Engineering segment.

Stevanato Group delivered a solid third quarter in 2025, achieving 9% revenue growth to €303.2 million, driven by a record 49% contribution from high-value solutions. The company expanded its gross profit margin to 29.2% and adjusted EBITDA margin to 25.7%, while maintaining its fiscal year 2025 guidance.

Stevanato Group delivered a solid second quarter in 2025, with revenue increasing by 8% to €280.0 million, driven by strong performance in the Biopharmaceutical and Diagnostic Solutions (BDS) Segment. The company also expanded its gross profit and adjusted EBITDA margins, while maintaining its fiscal year 2025 guidance.

Stevanato Group reported a 9% increase in revenue for the first quarter of 2025, reaching €256.6 million, primarily driven by strong performance in the Biopharmaceutical and Diagnostic Solutions segment. Gross profit and operating profit margins also improved. The company maintained its full-year revenue guidance but lowered its adjusted EBITDA and adjusted diluted EPS guidance to reflect the estimated impact of recently announced tariffs.

Stevanato Group reported Q4 2024 revenue of €330.6 million, a 3% increase year-over-year. The Biopharmaceutical and Diagnostic Solutions segment grew 7%, offsetting a 16% decline in the Engineering segment. Gross profit margin declined to 29.7%, impacted by vial destocking, while operating profit margin improved to 20.2%. Adjusted EPS was €0.19, reflecting cost management initiatives and strong performance in high-value solutions.